[1]TINETTI M E,STUDENSKI S A. Comparative effectiveness research and patients with multiple chronic conditions[J]. N Engl J Med,2011,364(26):2478-2481. DOI:10.1056/NEJMp1100535.
[2]WILLIAMS A,MANIAS E,WALKER R. Interventions to improve medication adherence in people with multiple chronic conditions:a systematic review[J]. J Adv Nurs,2008,63(2):132-143. DOI:10.1111/j.1365-2648.2008.04656.x.
[3]SIROIS C,LAROCHE M L,GUÉNETTE L,et al. Polypharmacy in multimorbid older adults:protocol for a systematic review[J]. Systematic Reviews,2017,6(1):104.
[4]GNJIDIC D,HILMER S N,BLYTH F M,et al. Polypharmacy cutoff and outcomes:five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes[J]. J Clin Epidemiol,2012,65(9):989-995. DOI:10.1016/j.jclinepi.2012.02.018.
[5]FRIED T R,O'LEARY J,TOWLE V,et al. Health outcomes associated with polypharmacy in community-dwelling older adults:a systematic review[J]. J Am Geriatr Soc,2014,62(12):2261-2272. DOI:10.1111/jgs.13153.
[6]GUTHRIE B,MAKUBATE B,HERNANDEZ-SANTIAGO V,et al. The rising tide of polypharmacy and drug-drug interactions:population database analysis 1995—2010[J]. BMC Medicine,2015,13(14):74. DOI:10.1186/s12916-015-0322-7.
[7]O'MAHONY D,O'SULLIVAN D,BYRNE S,et al. STOPP/START criteria for potentially inappropriate prescribing in older people:version 2[J]. Age Ageing,2015,44(2):213-218. DOI:10.1093/ageing/afx178.
[8]COOPER J A,CADOGAN C A,PATTERSON S M,et al. Interventions to improve the appropriate use of polypharmacy in older people:a Cochrane systematic review[J]. BMJ Open,2015,5(12):e009235. DOI:10.1136/bmjopen-2015-009235.
[9]MAHER R L,HANLON J,HAJJAR E R. Clinical consequences of polypharmacy in elderly[J]. Expert Opin Drug Saf,2014,13(1):57-65. DOI:10.1517/14740338.2013.827660.
[10]URFER M,ELZI L,DELL-KUSTER S,et al. Intervention to improve appropriate prescribing and reduce polypharmacy in elderly patients admitted to an internal medicine unit[J]. PLoS One,2016,11(11):e0166359. DOI:10.1371/journal.pone.0166359.
[11]KIM H A,SHIN J Y,KIM M H,et al. Prevalence and predictors of polypharmacy among Korean elderly[J]. PLoS One,2014,9(6):e98043. DOI:10.1371/journal.pone.0098043.
[12]MASNOON N,SHAKIB S,KALISCH-ELLETT L,et al. What is polypharmacy? A systematic review of definitions[J]. BMC Geriatr,2017,17(1):230. DOI:10.1186/s12877-017-0621-2.
[13]JOKANOVIC N,TAN E C,DOOLEY M J,et al. Prevalence and factors associated with polypharmacy in long-term care facilities:a systematic review[J]. J Am Med Dir Assoc,2015,16(6):535. DOI:10.1016/j.jamda.2015.03.003.
[14]ELMSTAHL S,LINDER H. Polypharmacy and inappropriate drug use among older people:a systematic review[J]. Healthy Aging & Clinical Care in the Elderly,2013,5(3642):1-8. DOI:10.4137/HACCE.S11173.
[15]HOY D,BROOKS P,WOOLF A,et al. Assessing risk of bias in prevalence studies:modification of an existing tool and evidence of interrater agreement[J]. J Clin Epidemiol,2012,65(9):934-939. DOI:10.1016/j.jclinepi.2011.11.014.
[16]MACAULAY S,DUNGER D B,NORRIS S A. Gestational diabetes mellitus in Africa:a systematic review[J]. PLoS One,2014,9(6):e97871. DOI:10.1371/journal.pone.0097871.
[17]陈月红,杜亮,耿兴远,等. 无对照二分类数据的Meta分析在RevMan软件中的实现[J]. 中国循证医学,2014,14(7):889-896.
[18]HIGGINS J P,THOMPSON S G. Quantifying heterogeneity in a meta-analysis[J]. Stat Med,2002,21(11):1539-1558. DOI:10.1002/sim.1186.
[19]ASSARI S,BAZARGAN M. Race/ethnicity,socioeconomic status,and polypharmacy among older americans[J]. Pharmacy(Basel),2019,7(2):41. DOI:10.3390/pharmacy7020041.
[20]CHARLESWORTH C J,SMIT E,LEE D S,et al. Polypharmacy among adults aged 65 years and older in the united states:1988—2010[J]. J Gerontol A Biol Sci Med Sci,2015,70(8):989-995. DOI:10.1093/gerona/glv013.
[21]GEORGE C,VERGHESE J. Polypharmacy and gait performance in community-dwelling older adults[J]. J Am Geriatr Soc,2017,65(9):2082-2087. DOI:10.1111/jgs.14957.
[22]HEUBERGER R A,CAUDELL K. Polypharmacy and nutritional status in older adults:a cross-sectional study[J]. Drugs Aging,2011,28(4):315-323. DOI:10.2165/11587670-000000000-00000.
[23]KANTOR E D,REHM C D,HAAS J S,et al. Trends in prescription drug use among adults in the united states from 1999—2012[J]. JAMA,2015,314(17):1818-1831. DOI:10.1001/jama.2015.13766.
[24]SHMUEL S,LUND J L,ALVAREZ C,et al. Polypharmacy and incident frailty in a longitudinal community-based cohort study[J]. J Am Geriatr Soc,2019,67(12):2482-2489. DOI:10.1111/jgs.16212.
[25]BAZARGAN M,SMITH J,YAZDANSHENAS H,et al. Non-adherence to medication regimens among older African-American adults[J]. BMC Geriatr,2017,17(1):163. DOI:10.1186/s12877-017-0558-5.
[26]RAMAGE-MORIN P L. Medication use among senior Canadians[J]. Health Rep,2009,20(1):37-44.
[27]REASON B,TERNER M,MCKEAG A M,et al. The impact of polypharmacy on the health of Canadian seniors[J]. Fam Pract,2012,29(4):427-432. DOI:10.1093/fampra/cmr124.
[28]SILVEIRA E A,DALASTRA L,PAGOTTO V. Polypharmacy,chronic diseases and nutritional markers in community-dwelling older[J]. Rev Bras Epidemiol,2014,17(4):818-829. DOI:10.1590/1809-4503201400040002.
[29]CARVALHO M F,ROMANO-LIEBER N S,BERGSTEN-MENDES G,et al. Polypharmacy among the elderly in the city of São Paulo,Brazil-SABE Study[J]. Rev Bras Epidemiol,2012,15(4):817-827. DOI:10.1590/s1415-790x2012000400013.
[30]DHALWANI N N,FAHAMI R,SATHANAPALLY H,et al. Association between polypharmacy and falls in older adults:a longitudinal study from England[J]. BMJ Open,2017,7(10):e016358. DOI:10.1136/bmjopen-2017-016358.
[31]RAWLE M J,RICHARDS M,DAVIS D,et al. The prevalence and determinants of polypharmacy at age 69:a British birth cohort study[J]. BMC Geriatr,2018,18(1):118. DOI:10.1186/s12877-018-0795-2.
[32]RICHARDSON K,ANANOU A,LAFORTUNE L,et al. Variation over time in the association between polypharmacy and mortality in the older population[J]. Drugs Aging,2011,28(7):547-560. DOI:10.2165/11592000-000000000-00000.
[33]DAVIES L E,KINGSTON A,TODD A,et al. Characterising polypharmacy in the very old:findings from the Newcastle 85+ Study[J]. PLoS One,2021,16(1):e0245648. DOI:10.1371/journal.pone.0245648.
[34]CARMONA-TORRES J M,COBO-CUENCA A I,RECIO-ANDRADE B,et al. Prevalence and factors associated with polypharmacy in the older people:2006—2014[J]. J Clin Nurs,2018,27(15/16):2942-2952. DOI:10.1111/jocn.14371.
[35]GUTIRREZ-VALENCIA M,ALDAZ HERCE P,LACALLE-FABO E,et al. Prevalence of polypharmacy and associated factors in older adults in Spain:data from the National Health Survey 2017[J]. Med Clin(Barc),2019,153(4):141-150. DOI:10.1016/j.medcli.2018.12.013.
[36]BLANCO-REINA E,ARIZA-ZAFRA G,OCAA-RIOLA R,et al. Optimizing elderly pharmacotherapy:polypharmacy vs.undertreatment. Are these two concepts related? [J]. Eur J Clin Pharmacol,2015,71(2):199-207. DOI:10.1007/s00228-014-1780-0.
[37]BLANCO-REINA E,GARCA-MERINO M R,OCAA-RIOLA R,et al. Assessing potentially inappropriate prescribing in community-dwelling older patients using the updated version of STOPP-START criteria:a comparison of profiles and prevalences with respect to the original version[J]. PLoS One,2016,11(12):e0167586. DOI:10.1371/journal.pone.0167586.
[38]FRANCHI C,TETTAMANTI M,PASINA L,et al.Changes in drug prescribing to Italian community-dwelling elderly people:the EPIFARM-Elderly Project 2000—2010[J].Eur J Clin Pharmacol,2014,70(4):437-443.DOI:10.1007/s00228-013-1621-6.
[39]NOBILI A,FRANCHI C,PASINA L,et al.Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project[J].Pharmacoepidemiol Drug Saf,2011,20(5):488-496.DOI:10.1002/pds.2108.
[40]VALENT F.Polypharmacy in the general population of a Northern Italian area: analysis of administrative data[J].Ann Ist Super Sanita,2019,55(3):233-239.DOI:10.4415/ANN_19_03_06.
[41]HAIDER S I,JOHNELL K,THORSLUND M,et al.Analysis of the association between polypharmacy and socioeconomic position among elderly aged > or =77 years in Sweden[J].Clin Ther,2008,30(2):419-427.DOI:10.1016/j.clinthera.2008.02.010.
[42]MOEN J,ANTONOV K,LARSSON C A,et al.Factors associated with multiple medication use in different age groups[J].Ann Pharmacother,2009,43(12):1978-1985.DOI:10.1345/aph.1M354.
[43]MORIN L,JOHNELL K,LAROCHE M L,et al.The epidemiology of polypharmacy in older adults: register-based prospective cohort study[J].Clin Epidemiol,2018,10(12):289-298.DOI:10.2147/CLEP.S153458.
[44]HERR M,ROBINE J M,PINOT J,et al.Polypharmacy and frailty:prevalence,relationship,and impact on mortality in a French sample of 2350 old people[J].Pharmacoepidemiol Drug Saf,2015,24(6):637-646.DOI:10.1002/pds.3772.
[45]HERR M,SIRVEN N,GRONDIN H,et al.Frailty,polypharmacy,and potentially inappropriate medications in old people:findings in a representative sample of the French population[J].Eur J Clin Pharmacol,2017,73(9):1165-1172.DOI:10.1007/s00228-017-2276-5.
[46]BARAT I,ANDREASEN F,DAMSGAARD E M.The consumption of drugs by 75-year-old individuals living in their own homes[J].Eur J Clin Pharmacol,2000,56(6/7):501-509.DOI:10.1007/s002280000157.
[47]BREKKE M,HUNSKAAR S,STRAAND J.Self-reported drug utilization, health, and lifestyle factors among 70-74 year old community dwelling individuals in Western Norway. The Hordaland Health Study (HUSK) [J].BMC Public Health,2006,6(1):121. DOI:10.1186/1471-2458-6-121.
[48]BUTTERY A K,BUSCH M A,GAERTNER B,et al.Prevalence and correlates of frailty among older adults: findings from the German health interview and examination survey[J].BMC Geriatr,2015,15(1):22.DOI:10.1186/s12877-015-0022-3.
[49]MIELKE N,HUSCHER D,DOUROS A,et al.Self-reported medication in community-dwelling older adults in Germany:results from the Berlin Initiative Study[J].BMC Geriatr,2020,20(1):22.DOI:10.1186/s12877-020-1430-6.
[50]CASTIONI J,MARQUES-VIDAL P,ABOLHASSANI N,et al.revalence and determinants of polypharmacy in Switzerland: data from the CoLaus study[J].BMC Health Serv Res,2017,17(1):840.DOI:10.1186/s12913-017-2793-z.
[51]JYRKKA J,VARTIAINEN L,HARTIKAINEN S,et al.Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study [J].Eur J Clin Pharmacol,2006,62(2):151-158.DOI:10.1007/s00228-005-0079-6.
[52]ÖNAL ÖZGÜR,DURUKAN ELIF.Frequency of polypharmacy and risk factors in the elderly in Burdur[J].Turkish Journal of Geriatrics,2018,21(4):550-556.DOI:10.31086/tjgeri.2018.61.
[53]MIDAO L,GIARDINI A,MENDITTO E,et al.Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe[J].Arch Gerontol Geriatr,2018,78:213-220.DOI:10.1016/j.archger.2018.06.018.
[54]NOGUCHI N,BLYTH F M,WAITE L M,et al.Prevalence of the geriatric syndromes and frailty in older men living in the community:the Concord Health and Ageing in Men Project[J].Australas J Ageing,2016,35(4):255-261.DOI:10.1111/ajag.12310.
[55]BEER C,HYDE Z,ALMEIDA OP,et al.Quality use of medicines and health outcomes among a cohort of community dwelling older men:an observational study [J].Br J Clin Pharmacol,2011,71(4):592-599.DOI:10.1111/j.1365-2125.2010.03875.x.
[56]PAGE A T,FALSTER M O,LITCHFIELD M,et al.Polypharmacy among older Australians,2006—2017: a population-based study[J].Med J Aust,2019,211(2):71-75.DOI:10.5694/mja2.50244.
[57]NISHTALA P S,SALAHUDEEN M S.Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period:2005—2013 [J].Gerontology,2015,61(3):195-202.DOI:10.1159/000368191.
[58]TAN Y W,SUPPIAH S,BAUTISTA M A,et al.Polypharmacy among community-dwelling elderly in Singapore: Prevalence, risk factors and association with medication non-adherence[J].Proceedings of Singapore Healthcare,2019,28(4):224-231.DOI.org/10.1177/2010105819868485.
[59]MERCHANT R A,CHEN M Z,TAN L W L,et al.Singapore healthy older people everyday(HOPE) study: prevalence of frailty and associated factors in older adults[J].J Am Med Dir Assoc,2017,18(8):734,e9-734,e14.DOI:10.1016/j.jamda.2017.04.020.
[60]LIM L M,MCSTEA M,CHUNG W W,et al.Prevalence,risk factors and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia[J].PLoS One,2017,12(3):e0173466.DOI:10.1371/journal.pone.0173466.
[61]JUNG H W,JANG I Y,LEE Y S,et al.Prevalence of frailty and aging-related health co6ditions in older Koreans in rural communities: a cross-sectional analysis of the aging study of Pyeongchang rural area[J].J Korean Med Sci,2016,31(3):345-352.DOI:10.3346/jkms.2016.31.3.345.
[62]LI I C,KUO H T,SIN M K,et al.Medication use in community-residing older adults in Taiwan: a comparison between conventional and complementary and alternative medications[J].J Community Health,2015,40(2):301-307.DOI:10.1007/s10900-014-9934-7.
[63]刘葳,于德华,金花,等.社区老年多病共存患者多重用药情况评价研究[J].中国全科医学,2020,23(13):1592-1598.DOI:10.12114/j.issn.1007-9572.2020.00.026. LIU W,YU D H,JIN H,et al.Analysis and evaluation of multiple drug use among elderly patients with multiple chronic conditions in community[J].Chinese General Practice,2020,23(13):1592-1598.DOI:10.12114/j.issn.1007-9572.2020.00.026.
[64]方向阳,陈清,候原平,等.社区老年人衰弱相关因素[J].中国老年医学,2019,39(2):467-470.DOI:10.3969/j.issn.1005-9202.2019.02.070.
[65]方向阳,陈清,陆政,等.社区老年人认知功能障碍与衰弱的关系研究[J].中国全科医学,2018,21(2):185-189.DOI.10.3969/j.issn.1007-9572.2017.00.031. FANG X Y,CHEN Q,LU M,et al.Relationship between cognitive impairment and frailty in community -dwelling elderly people[J].Chinese General Practice,2018,21(2):185-189.DOI.10.3969/j.issn.1007-9572.2017.00.031.
[66]章荣华,岳廷,朱艳兰.干休所老年人多重用药情况调查及对策[J].深圳中西医结合杂志,2015,25(2):182-183.DOI:10.16458/j.cnki.1007-0893.2015.02.104.
[67]刘淼,李嘉琦,吕宪玉,等.80岁老年人多重用药现况及影响因素分析[J].中国公共卫生,2017,33(3):412-414.DOI:10.11847/zgggws2017-33-03-18. LIU M,LI J Q,LYU X Y,et al.Prevalence and influencing factors of polypharmacy among persons aged 80 years or older[J].Chinese Journal of Public health,2017,33(3):412-414.DOI:10.11847/zgggws2017-33-03-18.
[68]AL-HASHAR A,AL-SINAWI H,AL-MAHRIZI A,et al.Prevalence and covariates of polypharmacy in elderly patients on discharge from a tertiary care hospital in Oman[J].Oman Med J,2016,31(6):421-425.DOI:10.5001/omj.2016.85.
[69]HUBBARD R E,PEEL N M,SCOTT I A,et al.Polypharmacy among inpatients aged 70 years or older in Australia[J].Med J Aust,2015,202(7):373-377.DOI:10.5694/mja13.00172.
[70]POUDEL A,PEEL N M,NISSEN L M,et al.Adverse outcomes in relation to polypharmacy in robust and frail older hospital patients[J].J Am Med Dir Assoc,2016,17(8):767,e9-767,e13.DOI:10.1016/j.jamda.2016.05.017.
[71]ONDER G,LIPEROTI R,FIALOVA D,et al.Polypharmacy in nursing home in Europe:results from the SHELTER study[J].J Gerontol A Biol Sci Med Sci,2012,67(6):698-704.DOI:10.1093/gerona/glr233.
[72]JOKANOVIC N,TAN E C,DOOLEY M J,et al.Prevalence and factors associated with polypharmacy in long-term care facilities:a systematic review[J].J Am Med Dir Assoc,2015,16(6):535,e1-12.DOI:10.1016/j.jamda.2015.03.003.
[73]RIECKERT A,TRAMPISCH U S,KLAAßEN-MIELKE R,et al.Polypharmacy in older patients with chronic diseases:a cross-sectional analysis of factors associated with excessive polypharmacy[J].BMC Fam Pract,2018,19(1):113.DOI:10.1186/s12875-018-0795-5.
[74]QUIONES AR,MARKWARDT S & BOTOSENEANU A.Multimorbidity combinations and disability in older adults[J].Biological Sciences and Medical Sciences,2916,71(6):823-830.DOI:10.1093/gerona/glw035.
[75]Counterweight Project Team.The impact of obesity on drug prescribing in primary care[J].Br J Gen Pract,2005,55(519):743-749.
[76]KAUFMAN D W,KELLY J P,ROSENBERG L,et al.Recent patterns of medication use in the ambulatory adult population of the United States[J].JAMA, 2002,287(3):337-344.DOI:10.1001/jama.287.3.337.
[77]JORGENSEN T,JOHANSSON S,KENNERFALK A,et al.Prescription drug use, diagnoses, and healthcare utilization among the elderly[J].Ann Pharmacother,2001,35:1004-1009.DOI:10.1345/aph.10351.
[78]BIERMAN A S,PUGH M J,DHALLA I,et al.Sex differences in inappropriate prescribing among elderly veterans[J].Am J Geriatr Pharmacother,2007,5(2):147-161.DOI:10.1016/j.amjopharm.2007.06.005.
|